(NASDAQ: VRDN) Viridian Therapeutics's forecast annual revenue growth rate of 919.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Viridian Therapeutics's revenue in 2025 is $302,000.On average, 3 Wall Street analysts forecast VRDN's revenue for 2025 to be $44,816,723, with the lowest VRDN revenue forecast at $24,445,485, and the highest VRDN revenue forecast at $81,484,950. On average, 6 Wall Street analysts forecast VRDN's revenue for 2026 to be $4,165,103,219, with the lowest VRDN revenue forecast at $1,229,607,896, and the highest VRDN revenue forecast at $7,521,060,885.
In 2027, VRDN is forecast to generate $29,666,225,747 in revenue, with the lowest revenue forecast at $14,013,781,701 and the highest revenue forecast at $79,903,327,121.